摘要
目的:从社会角度比较两种分子差向异构体甘草酸制剂用于慢性乙型肝炎患者保肝治疗的疗效及经济学差异。方法:140例慢性乙型肝炎患者随机分为A(71例)、B(69例)两组,分别采用异甘草酸镁和复方甘草酸单铵S保肝治疗。比较两组肝功能指标变化和临床疗效,以及药品不良反应发生情况,并进行成本-效果分析和敏感度分析。结果:治疗后,两组患者各项肝功能指标均较前明显降低(P<0.05),而两组间无明显差异(P>0.05)。A组临床总有效率为80.28%,明显高于B组的65.22%(P<0.05)。两组药品不良反应发生率无明显差异(P>0.05)。A组的成本效果比(C/E)明显大于B组,增量成本效果比(ΔC/ΔE)为9573.84;调整后A组成本效果比(C′/E′)仍大于B组,增量成本效果比(ΔC′/ΔE′)为8374.10。结论:异甘草酸镁保肝治疗临床疗效优于复方甘草酸单铵S,但成本-效果分析与敏感度分析显示,复方甘草酸单铵S治疗更具有经济学优势。
Objective:To evaluate the clinical efficacy and economics differences of two molecular epimer glycyrrhizic acid preparations in patients with chronic hepatitis B from a social perspective. Methods:140 patients with chronic hepatitis B were randomly divided into A(71 cases) and B(69 cases) groups. They were treated respectively with magnesium isoglycyrrhizinate and compound monoammonium glycyrrhizinate S, respectively, to keep the liver function. The changes of liver function indexes and clinical efficacy, as well as the occurrence of adverse drug reactions between the two groups were compared, and cost-effectiveness analysis and sensitivity analysis were performed. Results: After treatment, the liver function indexes of the two groups were significantly lower than before(P<0.05), but there was no significant difference between the two groups(P>0.05). The total clinical effective rate of group A was 80.28%, which was significantly higher than 65.22% of group B(P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05). The cost-effectiveness ratio(C/E) of group A was significantly greater than that of group B, and the incremental cost-effectiveness ratio(ΔC/ΔE) was 9 573.84;after adjustment, the cost-effectiveness ratio(C′/E′) of group A was still greater than that of group B. The cost-effectiveness ratio(ΔC′/ΔE′) was 8 374.10.Conclusion:The clinical effect of magnesium isoglycyrrhizinate was better than that of compound monoammonium glycyrrhizinate S, but cost-effectiveness analysis and sensitivity analysis showed that compound monoammonium glycyrrhizinate S has more economic advantages.
作者
王旭
陈红斗
刘瑞霞
余舒乐
郑芳芳
叶露
丁跃辉
Wang Xu;Chen Hongdou;Liu Ruixia;Yu Shule;Zheng Fangfang;Ye Lu;Ding Yuehui(Department of Pharmacy,Suqian People’s Hospital of Nanjing Drum-Tower Hospital Group,Suqian 223800,Jiangsu,China;Department of Pharmacy,Affiliated Suqian Hospital of Xuzhou Medical University;Department of Infectious Disease,Suqian People's Hospital of Nanjing Drum-Tower Hospital Group;Department of Infectious Disease,Affiliated Suqian Hospital of Xuzhou Medical University)
出处
《药物流行病学杂志》
CAS
2021年第7期482-485,共4页
Chinese Journal of Pharmacoepidemiology
基金
江苏省高层次卫生人才“六个一工程”拔尖人才科研项目(编号:LGY2019054)
江苏省药学会天晴医院药学科研项目(编号:Q2018080)。
关键词
异甘草酸镁
复方甘草酸单铵S
慢性乙型肝炎
疗效
成本-效果分析
Magnesium isoglycyrrhizinate
Compound monoammonium glycyrrhizinate S
Chronic hepatitis B
Efficacy
Cost-effectiveness analysis
